MabVax Therapeutics Receives Two Small Business Technology Transfer Program Awards From The National Cancer Institute
Earlier this year, MabVax completed two licensing agreements with Sloan-Kettering Institute for Cancer Research, the research arm of Memorial Sloan-Kettering Cancer Center (MSKCC), for exclusive development and commercialization rights to multiple vaccines against selected recurrent cancers. MSKCC has already initiated Phase I clinical trials with two different vaccines to demonstrate immunogenicity and tolerability in sarcoma and breast cancer. The first STTR award will support work on a Phase I small cell lung cancer trial to be conducted by MSKCC early next year, with MabVax providing laboratory analysis support. The second STTR award will support MabVax’s efforts to isolate human antibodies from immunized patients participating in those Phase I trials.
“The STTR awards will offset early expenses that both MSKCC and MabVax will incur as we continue to execute our plans to initiate MabVax sponsored Phase II cancer vaccine clinical trials in sarcoma and small cell lung cancer in the coming year. MabVax will simultaneously build a pipeline of fully human monoclonal antibody products against each of the antigenic targets utilized in the vaccines,” said
About MabVax Therapeutics, Inc.
MabVax was formed to commercialize the work of Dr.
SOURCE MabVax Therapeutics Inc.